A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of RO7079901 Administered Intravenously Both Alone and in Combination With Meropenem in Adult Healthy Volunteers
Latest Information Update: 17 Feb 2020
At a glance
- Drugs Meropenem (Primary) ; Nacubactam (Primary)
- Indications Bacterial infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Roche
- 10 Feb 2020 Results evaluating the pharmacokinetics and safety of single and multiple escalating doses of nacubactam in healthy volunteers published in the Antimicrobial Agents and Chemotherapy
- 24 Apr 2018 Results presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases
- 20 Apr 2017 Status changed from recruiting to completed.